A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

A 5-year-old boy from Center City has faced rare odds since birth and now this warrior is in a real life race to rewrite his story.

Medically reviewed by Danielle Weiss, MD When women have high testosterone, the primary hormone in people assigned male at ...

Growth Hormone-Releasing Peptide-2 (GHRP-2) is a synthetic hexapeptide that has garnered significant attention in the ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for gestational age (SGA), with Noonan syndrome (NS), or with idiopathic short stature ...

According to Novo Nordisk, non-adherence to daily injections is a common problem in children with growth hormone disorders and can cause compliance problems, preventing them from achieving their ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya (somapacitan) in four different but related growth disorder indications ...

Somapacitan was noninferior to somatropin in improving yearly growth rate in children born SGA, or with NS or ISS. Topline data were announced from a phase 3 trial evaluating somapacitan in pre ...

Sogroya showed 11.0 cm/year growth in SGA children vs 9.4 cm/year with low-dose somatropin and 11.1 cm/year with high-dose. In Noonan syndrome, Sogroya achieved 10.4 cm/year height gain vs 9.2 cm ...